Jordan Julie 4

What Happened
Julie Jordan, Chief Medical Officer of Neurogene, sold 828 shares on March 26, 2026. The shares were sold at a weighted-average price of $21.89 for total proceeds of approximately $18,128. This sale was a mandatory portion of an RSU vesting event to satisfy tax withholding; it is not an open discretionary sell decision.

Key Details

• Transaction date: March 26, 2026; Form 4 filed March 30, 2026 (timely within the 2-business-day requirement).
• Sale: 828 shares disposed; weighted-average price $21.89; prices ranged $21.68–$22.19 across multiple executions.
• Proceeds: ~ $18,128.
• Reason/footnote: Sale relates exclusively to mandatory share sale to cover tax withholding on RSU vesting (Footnote F1).
• Holdings after transaction: The filing does not state total shares owned following this sale.
• Additional award detail (Footnote F3): Reporting person has outstanding RSUs — 5,600 units vesting in equal installments on 3/26/2027 and 3/26/2028, and 4,900 units vesting in equal installments on 2/20/2027, 2/20/2028, and 2/20/2029, subject to continued service.

Context

• This was a tax-withholding sale triggered by RSU vesting (a routine administrative sale), not a discretionary open-market liquidation decision. Such mandatory sell-to-cover transactions are common following equity awards and do not necessarily signal insider sentiment about the company.